A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer

NCT03707028 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated after completion of Part 1 due to a change in research plan.

Conditions

Gastric Cancer
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Rivoceranib
DRUG: Paclitaxel

Sponsor

Elevar Therapeutics